Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

Galapagos 100 euro per aandeel

1.208 Posts
Pagina: «« 1 ... 25 26 27 28 29 ... 61 »» | Laatste | Omlaag ↓
  1. [verwijderd] 25 januari 2017 23:07
    Branchegenoot van Galapagos maakt geld.

    VERTEX
    Full-Year 2016 Financial Highlights Revenues:
    • Total CF revenues were $1.68 billion compared to $982.3 million for 2015.
    • Net product revenues from ORKAMBI were $979.6 million compared to $350.7 million for 2015 . ORKAMBI was launched
    in the U.S. in July 2015.
    • Net product revenues from KALYDECO were $703.4 million compared to $631.7 million for 2015 .

    GAAP net loss was $(112.1) million , or $(0.46) per diluted share, compared to Vertex's 2015 GAAP net loss of $(556.3) million , or $(2.31) per diluted share. Non-GAAP net income was $211.2 million , or $0.85 per diluted share, compared to a non-GAAP net loss of $(267.3) million , or $(1.11) per diluted share, for 2015 . The decreased net loss on a GAAP basis and the change to net income on a non-GAAP basis was the result of a full year of ORKAMBI product revenues and increased KALYDECO product revenues, partially offset by increased operating expenses.

    files.shareholder.com/downloads/VRTX/...

    Koers 100 euro Galapagos dichter bij, dan menigeen denkt.
  2. [verwijderd] 26 januari 2017 08:43
    quote:

    inspirator schreef op 25 januari 2017 23:07:

    Branchegenoot van Galapagos maakt geld.

    VERTEX
    Full-Year 2016 Financial Highlights Revenues:
    • Total CF revenues were $1.68 billion compared to $982.3 million for 2015.
    • Net product revenues from ORKAMBI were $979.6 million compared to $350.7 million for 2015 . ORKAMBI was launched
    in the U.S. in July 2015.
    • Net product revenues from KALYDECO were $703.4 million compared to $631.7 million for 2015 .

    GAAP net loss was $(112.1) million , or $(0.46) per diluted share, compared to Vertex's 2015 GAAP net loss of $(556.3) million , or $(2.31) per diluted share. Non-GAAP net income was $211.2 million , or $0.85 per diluted share, compared to a non-GAAP net loss of $(267.3) million , or $(1.11) per diluted share, for 2015 . The decreased net loss on a GAAP basis and the change to net income on a non-GAAP basis was the result of a full year of ORKAMBI product revenues and increased KALYDECO product revenues, partially offset by increased operating expenses.

    files.shareholder.com/downloads/VRTX/...

    Koers 100 euro Galapagos dichter bij, dan menigeen denkt.

    Forget Incyte: Gilead Sciences Would Be Better Off Buying 'Galapagos'

    Read more: www.fool.com/investing/2017/01/25/for...

    Galapagos looks like a steal

    Compared to Incyte, Galapagos is relatively cheap at just $3.2 billion. That's a reasonable valuation for a company without a product on the market. But if Gilead Sciences is looking for products that could reach market quickly, or a large influx of new shots on goal, then it would be difficult to find a better target than Galapagos.

    The Belgium biotech boasts one phase 3 trial, four phase 2 trials, three phase 1 trials, five preclinical trials, and 20 discovery programs. That includes programs for osteoarthritis and cystic fibrosis, partnered with Servier and AbbVie , respectively. Its most advanced drug candidate, a JAK1 inhibitor called filgotinib, is partnered with Gilead Sciences in three separate trials targeting rheumatoid arthritis, Crohn's disease, and ulcerative colitis.

    The collaboration didn't come cheap. Gilead Sciences paid $300 million up front and made a $425 million equity investment in the innovative upstart. Galapagos is also entitled to receive milestone payments of up to $755 million, sales-based milestone payments of up to $600 million, and tiered royalties on global sales that start at 20%. That's a lot of dough, partially because the market opportunity for the three autoimmune diseases is enormous. The global markets for ulcerative colitis and Crohn's disease alone are expected to reach a combined $11 billion by 2022.

    The growth potential is impressive for successful therapies -- and so are the potential milestone payments. Luckily, Gilead Sciences' equity investment may prove strategic. How so? It means the Hepatitis C pioneer now owns 14.7% of Galapagos, which would make any potential acquisition 14.7% cheaper. If the company's pipeline heats up and other biopharmas start inquiring about an acquisition, then Gilead Sciences owns a sweet bidding advantage over its peers.

    Read more: www.fool.com/investing/2017/01/25/for...

  3. [verwijderd] 30 januari 2017 20:09
    One of those drugs is filgotinib, an autoimmune disease drug Gilead Sciences is co-developing with Galapagos NV. Filgotinib recently entered phase 3 studies for use in rheumatoid arthritis, Crohn's disease, and ulcerative colitis. A clean safety profile in mid-stage studies and oral dosing could make it a top-seller someday.

    Ready to make a deal
    Keith Speights: For those who think Gilead's future looks dim, remember that the biotech's stock nearly tripled over the past five years primarily because of an acquisition. Back in November 2011, Gilead bought Pharmasset for $11 billion, picking up the hepatitis C virus (HCV) drug later to be known as Sovaldi. Combinations of Sovaldi with other drugs led to the successful commercial launches of two other HCV drugs, Harvoni and Epclusa.

    Gilead has more money -- and more motivation -- to make a game-changing acquisition than it did a little over five years ago. The biotech reported $31.6 billion in cash, cash equivalents, and marketable securities at the end of the third quarter of 2016. With its strong operating cash flow, Gilead undoubtedly has more than that now.

    CEO John Milligan has publicly stated that the company is focused on "augmenting [its] portfolio with external opportunities, particularly in the field of oncology." However, Milligan didn't limit Gilead's acquisition prospects to only oncology.

    I don't expect the biotech to merely throw money at an acquisition in the hopes that it pays off; Gilead's management team is too disciplined to make a rash decision. However, it won't surprise me if Gilead makes one or more deals in 2017 that pay off for investors over the long run.

    www.fool.com/investing/2017/01/30/why...
  4. [verwijderd] 29 maart 2017 16:55
    quote:

    springinhetveld schreef op 4 maart 2016 17:02:

    Die "inspirator" toch. Vorig jaar had hij ook zo een leuk fantasie draadje:
    "koers MDxHealth naar 15,25 en later naar 47 euro"

    Die staan momenteel op 3,50 (komen net van 2,90). Weet niet wat er mis is met deze jonge of wat hij er mee wil berijken. Heeft iig een zeer levendige fantasie en is zeer positief ingesteld. Maar om nou veel waarde aan zijn woorden te hechten......nö geloof niet dat dat verstandig is.

    Erkenning komt pas later !
  5. forum rang 10 voda 29 maart 2017 21:10
    quote:

    inspirator schreef op 4 maart 2016 01:01:

    Overvolle pijplijn Galapagos met 1,2 miljard cash.

    Stijging koers Galapagos naar 100 euro in verschiet.
    Zat je er toen in Inspirator? (en tegen welke koers?)

    De slotkoers toen, 4 maart 2016 was 40.50.

    Bijna een verdubbeling in 1 jaar tijd!

    www.iex.nl/Aandeel-Koers/60189120/Gal...
  6. pardon 6 april 2017 16:39
    quote:

    inspirator schreef op 29 maart 2017 16:51:

    MdxHealth wordt volgende succesnummer !
    Ik hoop dat je gelijk hebt,ik reken zelf binnen 2 jaar op 10 euro. maar mag ook meer zijn.
    Bij Gala dacht ik ook binnen 2 jaar 42 euro nu is het ook al bijna 84 euro.
  7. forum rang 10 voda 7 april 2017 20:49
    quote:

    inspirator schreef op 7 april 2017 20:31:

    Verschil koers Galapagos MdxHealth vandaag opgelopen naar 4 %.
    Ja, en wat wil je hiermee zeggen?
  8. forum rang 6 de tuinman 8 april 2017 14:17
    quote:

    voda schreef op 7 april 2017 20:49:

    [...]
    Ja, en wat wil je hiermee zeggen?
    Hij maakt reclame voor zijn eigen aandelen.
1.208 Posts
Pagina: «« 1 ... 25 26 27 28 29 ... 61 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.017
AB InBev 2 5.496
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.650
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.645
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.751
Aedifica 3 916
Aegon 3.258 322.831
AFC Ajax 538 7.088
Affimed NV 2 6.296
ageas 5.844 109.892
Agfa-Gevaert 14 2.050
Ahold 3.538 74.336
Air France - KLM 1.025 35.043
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.823
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.180
AMG 971 133.335
AMS 3 73
Amsterdam Commodities 305 6.689
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 14.998
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.776
Arcelor Mittal 2.033 320.706
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.300
Aroundtown SA 1 219
Arrowhead Research 5 9.737
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.096
ASML 1.766 107.183
ASR Nederland 21 4.485
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.667
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392

Macro & Bedrijfsagenda

  1. 24 februari

    1. Vastned Q4-cijfers
    2. PostNL Q4-cijfers
    3. Ifo ondernemersvertrouwen februari (Dld)
    4. Inflatie januari def. (eur)
    5. Chicago Fed index januari (VS)
    6. Retail Estates Q3-cijfers
    7. Vastned Belgium Q4-cijfers
    8. Zoom Video Communications Q4-cijfers (VS)
    9. Hims & Hers Health - Q4-cijfers
  2. 25 februari

    1. Ackermans & Van Haaren Q4-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht